Investigation into the Cost-Effectiveness of Extended Posttraumatic Thromboprophylaxis

Keyphrases

• Cost-effectiveness 100%
• Post-traumatic 100%
• Thromboprophylaxis 100%
• Rivaroxaban 100%
• Venous Thromboembolism 50%
• Quality-adjusted Life Years 50%
• High Risk 33%
• Trauma Patients 33%
• Probabilistic Sensitivity Analysis 33%
• One-way Sensitivity Analysis 33%
• Pulmonary Embolism 16%
• Deep Vein Thrombosis 16%
• Oncology 16%
• Decision Tree 16%
• Cost-utility 16%
• Enoxaparin 16%
• Extended Thromboprophylaxis 16%
• Severely Injured Patients 16%
• Post-thrombotic Syndrome 16%
• Dabigatran 16%
• Risk Index 16%
• Venous Thromboembolism Risk 16%
• Willingness-to-pay Threshold 16%
• Markov Process 16%
• Apixaban 16%
• Chronic Thromboembolic Pulmonary Hypertension (CTEPH) 16%
• Dominant Strategy 16%
• Subspeciality 16%
• Fondaparinux 16%
• Utility Model 16%
• Alternative Regimens 16%
• Pulmonary Bleeding 16%
• Robust Preferences 16%

Medicine and Dentistry

• Cost-Effectiveness Analysis 100%
• Thromboprophylaxis 100%
• Rivaroxaban 100%
• Venous Thromboembolism 66%
• Health Care Cost 50%
• Quality Adjusted Life Year 50%
• Preference 33%
• Prospective Study 16%
• Sequela 16%
• Pulmonary Embolism 16%
• Deep Vein Thrombosis 16%
• Oncology 16%
• Post-Thrombotic Syndrome 16%
• Dabigatran 16%
• Apixaban 16%
• Fondaparinux 16%
• Chronic Thromboembolic Pulmonary Hypertension 16%
• Oral 16%